Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Dawnrays Pharmaceutical (Holdings) Limited
  6. Summary
    2348   KYG2687M1006

DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED

(2348)
  Report
 SummaryChartsNewsCalendarCompanyFinancials 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Exchange
10/12/2021 10/15/2021 10/18/2021 10/19/2021 10/20/2021 Date
1.72 1.68 1.68 1.7 1.65 Last
532000 684000 653000 396000 156000 Volume
-0.58% -2.33% 0.00% +1.19% -2.94% Change
Estimated financial data (e)
Sales 2019 950 M 149 M 149 M
Net income 2019 255 M 39,9 M 39,9 M
Net cash position 2019 928 M 145 M 145 M
P/E ratio 2019 8,82x
Yield 2019 3,63%
Sales 2020 1 024 M 160 M 160 M
Net income 2020 268 M 41,9 M 41,9 M
Net cash position 2020 959 M 150 M 150 M
P/E ratio 2020 8,07x
Yield 2020 3,91%
Capitalization 2 032 M 318 M 318 M
EV / Sales 2019 1,11x
EV / Sales 2020 0,79x
Nbr of Employees 1 025
Free-Float 39,4%
More Financials
Company
Dawnrays Pharmaceutical (Holdings) Limited is an investment holding company principally engaged in the development, manufacture and sale of non-patented pharmaceutical medicines. The products include intermediate pharmaceutical, bulk medicines and finished drugs. The Company operates its business through two segments. The Intermediates and Bulk Medicines segment is engaged in the manufacture and sale of... 
Sector
Pharmaceuticals
Calendar
03/25Earnings Release
More about the company
All news about DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED
09/24DAWNRAYS PHARMACEUTICAL : Arm Seeks Marketing Nod for Injectable Products in China
MT
09/20DAWNRAYS PHARMACEUTICAL (HOLDINGS) L : Ex-dividend day for interim dividend
FA
09/15Tranche Update on Dawnrays Pharmaceutical Limited's Equity Buyback Plan announced on Au..
CI
09/10DAWNRAYS PHARMACEUTICAL : Akeso Raise Joint Venture Capital, Start Phase Three Clinical Tr..
MT
09/09Dawnrays Pharmaceutical Limited Announces Initiation of Phase III Clinical Trial for Pr..
CI
08/27Dawnrays Pharmaceutical Limited Announces Semi Annual Dividend for the Year Ended Decem..
CI
08/27Dawnrays Pharmaceutical Holdings Limited Reports Earnings Results for the Half Year End..
CI
06/01DAWNRAYS PHARMACEUTICAL (HOLDINGS) L : Ex-dividend day for extraordinary dividend
FA
06/01DAWNRAYS PHARMACEUTICAL (HOLDINGS) L : Ex-dividend day for final dividend
FA
05/28Dawnrays Pharmaceutical Limited Approves Special Dividend for the Year Ended 31 Decembe..
CI
05/28Dawnrays Pharmaceutical Limited Declares Dividend for the Year Ended December 31, 2020
CI
05/28Dawnrays Pharmaceutical Limited's Equity Buyback announced on August 27, 2020, has expi..
CI
04/19DAWNRAYS PHARMACEUTICAL : Form of proxy for use at the Annual General Meeting of the Compa..
PU
04/19DAWNRAYS PHARMACEUTICAL : Proposals for general mandates to issue and repurchase shares; r..
PU
04/19Dawnrays Pharmaceutical Limited Recommends Special Dividend for the Year Ended 31 Decem..
CI
More news
News in other languages on DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED

- No features available -

More news
Chart DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED
Duration : Period :
Dawnrays Pharmaceutical (Holdings) Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Managers and Directors
Shao Jun Chen Chief Executive Officer & Executive Director
Kei Ling Li Chairman
Tung Sing Lo Independent Non-Executive Director
Hao Xi Ede Independent Non-Executive Director
Ming Yee Lam Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED17.86%318
JOHNSON & JOHNSON4.07%431 148
ROCHE HOLDING AG13.98%333 101
PFIZER, INC.14.34%239 966
NOVO NORDISK A/S56.26%238 738
ELI LILLY AND COMPANY44.35%220 952